Form 4 for FULC Fulcrum Therapeutics, Inc.
Accepted 2024-03-08 00:00:00 ET · period of report 2024-03-08 · accession 0000950170-24-028827 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-08 | 2024-03-08 | FULC | Tourangeau Greg | VP, Fin | S - Sale | $11.72 | -4,884 | 11.8K | -29% | -$57.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-08 | S | D | 4,884 | $11.72 | 11,807 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.71 to $11.74, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. (F2) Includes 699 shares acquired under the Issuer's employee stock purchase plan on May 13, 2022. |